Chargement en cours...

HDAC inhibition as a treatment concept to combat temsirolimus-resistant bladder cancer cells

INTRODUCTION: Although the mechanistic target of rapamycin (mTOR) might be a promising molecular target to treat advanced bladder cancer, resistance develops under chronic exposure to an mTOR inhibitor (everolimus, temsirolimus). Based on earlier studies, we proposed that histone deacetylase (HDAC)...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Oncotarget
Auteurs principaux: Juengel, Eva, Najafi, Ramin, Rutz, Jochen, Maxeiner, Sebastian, Makarevic, Jasmina, Roos, Frederik, Tsaur, Igor, Haferkamp, Axel, Blaheta, Roman A.
Format: Artigo
Langue:Inglês
Publié: Impact Journals LLC 2017
Sujets:
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5746361/
https://ncbi.nlm.nih.gov/pubmed/29299126
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.22454
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!